secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001193125-24-223282
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M
--------------------------------------------------------------------------------

- BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.
- BioAtla eligible for up to $133.5M total, including $15M upfront/near-term milestones and $118.5M in future milestones plus tiered royalties.
- BioAtla enters Global Transaction Agreement with Himalaya Therapeutics, consenting to license and sharing a mid-teens percentage of upfront/milestone payments.
- Context may terminate at will; BioAtla may terminate if Context halts development for 8 consecutive quarters.
- BioAtla agrees to refrain from competitive activities regarding Nectin-4 bispecific/multi-specific antibodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312524223282/0001193125-24-223282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312524223282/d845616d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-223282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer